Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
Innovation-minded executives share their thoughts and predictions for the year ahead.
The most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
To remain relevant, speakers bureaus must evolve to a strategic marketing tactic with personalized messaging to the customer.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
This year's offering includes access to the most current and in-depth data on salary and compensation trends, job satisfaction, recruitment and retention tactics, and more.
Read the October 2017 issue in its entirety, including our Career and Salary Survey.
The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.
The successes of these pharma execs show that there's no one path to professional bliss.
Now that Facebook, Apple, and Google have set their sights on healthcare, agencies find themselves under pressure from yet another flank.